Pharma BD Deal Intelligence
Takeda acquired Nycomed for ~$13.7B (EUR 9.6B).
Takeda completes acquisition and names new CEO of Nycomed, completing the 9.6 billion Euro deal to acquire the Zurich-headquartered pharmaceutical company.
Takeda completes acquisition of Nycomed, gaining a significant presence in Europe and emerging markets with Nycomeds annual revenue of more than 2.8 billion…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Takeda Pharmaceutical acquired Nycomed for EUR 9.6B (~$13.7B) on a cash-free, debt-free basis; announced May 19, 2011 and completed September 30, 2011, giving Takeda a major European/emerging-markets footprint (Nycomed ~EUR 2.8B revenue) and the roflumilast (Daxas) COPD franchise.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / Nycomed (this deal) | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
| Takeda Pharmaceutical Company Ltd. / Insilico Medicine Inc. | 2026 | $600M | 54 |
← Browse all deals · How we score deals
More: 2011 deals · Takeda Pharmaceutical Company Ltd. deals · Metabolic deals